NewAmsterdam Pharma said Tuesday its cholesterol drug lowered the risk of major cardiovascular events and the biotech stock ...
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) revealed topline data from its Phase 3 BROADWAY clinical trial evaluating ...
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of ...
Dutch clinical-stage drug developer NewAmsterdam Pharma saw its shares close up 41% at $26.19 yesterday on positive research ...
Serge Belanger, an analyst from Needham, maintained the Buy rating on NewAmsterdam Pharma Company (NAMS – Research Report). The associated ...
NewAmsterdam Pharma Company N.V. (NAMS), a late-stage, clinical biopharmaceutical company, Tuesday announced positive topline data ...
The findings add to evidence that the company’s drug, obicetrapib, could change the narrative surrounding a once-abandoned ...
NewAmsterdam Pharma (Nasdaq: NAMS) took a commanding leap in the stock market, thanks to the announcement of positive topline data from its Phase 3 BROADWAY clinical trial. This trial evaluated ...
NewAmsterdam Pharma said Tuesday its cholesterol drug lowered the risk of major cardiovascular events and the biotech stock ...
Check the time stamp on this data. Updated AI-Generated Signals for Newamsterdam Pharma Company N.v. Warrant (NAMSW) ...
NewAmsterdam is singing data from its Broadway heart disease trial, hailing another phase 3 win for its cholesterol-busting ...
Investor's Business Daily on MSN21h
UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's DrugUniQure stock nearly doubled Tuesday after the company reached a testing agreement with the FDA for its Huntington's disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback